With the continuous advancement of the "Healthy China 2030" strategy, a multi-level security model is becoming a new trend. How to coordinate various industries to jointly contribute has become a focus of attention among industry insiders. On September 21, Shanghai Pharmaceuticals Holding, China Re Life Insurance, Meixin Health, and BCG jointly held the "Summit Forum on Building a Multi-level Medical Security System – and the 2020 China Oncology Specialty Drug Payment Report Release Conference," discussing the challenges and opportunities of the multi-level medical security system with 200 industry elites.

　　At the meeting, Li Yongzhong, Executive Director and Vice President of Shanghai Pharmaceuticals, and General Manager of Shanghai Pharmaceuticals Holding, attended and delivered a speech. "In recent years, the country has continuously promoted medical system reform centered on the 'three medical linkages,' driving drug price reductions through zero markup on drugs, '4+7' volume-based procurement, national medical insurance negotiations for anti-cancer drugs, and other measures to reduce patient burdens. Especially with the establishment of the Medical Insurance Bureau as a super purchaser, it has had a huge impact on the entire medical and pharmaceutical industry. The medical reform driven strongly by payers as the core force is pushing industrial transformation. Building a sustainable, multi-level medical security system covering the entire population is the main theme." According to Li Yongzhong, Meixin Health, incubated by Shanghai Pharmaceuticals Investment, has become a leader in innovative medical payment after three years of development. By cooperating with pharmaceutical companies, insurance, and other industry parties, it has launched various payment solutions such as pharmaceutical installment plans, drug benefits, commercial insurance, and city-customized welfare insurance, actively helping Chinese patients solve payment problems.

　　Currently, there are still certain gaps in China's medical security system, especially in the field of tumor treatment where costs are relatively high. The market for oncology specialty drugs is growing rapidly, but the payment capacity of tumor patients is relatively limited. Under the guidance of establishing a multi-level medical security system, it is particularly important to help other payers beyond basic medical insurance better alleviate payment pressure and fill payment gaps, thereby reducing patient burdens and improving the accessibility of oncology specialty drugs. At the meeting, Meixin Health, together with BCG and China Re Life Insurance, jointly released the "China Oncology Specialty Drug Payment Report (2020) Summary Edition," starting from the scale of the Chinese oncology specialty drug market, analyzing the current status of oncology specialty drug payments, and providing outlooks and suggestions on how the multi-level security system can support oncology specialty drug payments.

　　With the continuous deepening of medical reform, the top-level architecture of the multi-level security system has been formed, but the connectivity and coordination among various levels are still poor. Therefore, further optimization measures are needed to promote the development of the multi-level medical security system, including strengthening the triple protection functions of basic medical insurance, critical illness insurance, and medical assistance, accelerating the improvement of commercial health insurance's protection and service capabilities, and encouraging other payers to actively participate. "As an important part of the social security system, the insurance and pharmaceutical industries joining hands to actively participate in implementing the 'Healthy China' strategy and focusing on the development of medical and health undertakings is not only an unavoidable historical mission but also an inevitable requirement for their own development," said Mr. Zhang Xiaodong, CEO of Meixin Health.

　　In the long run, the establishment of a multi-level security system requires joint efforts from the government, commercial insurance companies, pharmaceutical companies, third-party service companies, associations, and think tanks. This forum also gathered experts from these fields, who had enthusiastic discussions on how to create a multi-level payment system. At the meeting, representatives from Shanghai Pharmaceuticals Holding, China Re Life Insurance, Meixin Health, Shanghai Chuangqi Health Development Research Institute, BCG, pharmaceutical companies, insurance companies, and other organizations jointly proposed establishing a long-term communication mechanism to create a cross-industry exchange platform called the "Pharmaceutical Insurance Industry Innovation Alliance." This alliance can regularly hold exchanges and seminars in the future, aiming to promote cross-industry integration and communication, and assist in building a multi-level medical security system.

　　Fifteen guests, including Li Yongzhong, General Manager of Shanghai Pharmaceuticals Holding; Tian Meipan, General Manager of China Re Life Insurance; Lu Yindi, Vice President of China Pharmaceutical Commerce Association; Zhang Xiaodong, CEO of Meixin Health; Liu Bin, General Manager of Shanghai Yun Health; Wu Chun, Managing Director and Global Partner of BCG; Zhou Hong, President of Roche Pharmaceuticals China; Chen Siyuan, General Manager of Bristol-Myers Squibb Mainland China and Hong Kong; Yin Min, General Manager of AstraZeneca Oncology Division; Wu Qingyi, Chief Business Officer of BeiGene; Qian Yun, Head of Market Access at Pfizer; and Jin Xiaodong, Chief Business Officer of InnoCare Pharma, participated in the establishment ceremony.

　　According to estimates from the Oncology Specialty Drug Payment Report, most of the payments for oncology specialty drugs in China are currently fully borne by patients themselves, followed by the medical insurance fund, while the burden proportion of other multi-level security and innovative payments is relatively low. The report specifically provides multiple suggestions regarding the roles and functions of medical insurance and commercial insurance as payers, as well as their coordination with other multi-level security systems, hoping to use the representative oncology specialty drugs as a starting point to offer ideas for building a broader multi-level security system. The full report will be officially released in November along with the Chinese Academy of Social Sciences' "China Health Insurance Blue Book" series.